The 80 patients had failed on multiple therapies and were only expected to have 2-4 months of median survival.
- The response rate (PSA reduction and tumor shrinkage) was 75%
- Most were still alive 6 months after the therapy
- Dry mouth was the only side effect of treatment
Anyone interested in medical tourism to try this experimental therapy can contact Dr. Haberkorn at the University of Heidelberg (he speaks English):
Phone: 06221 56-7731
There is a Phase 1 (dose finding) clinical trial of Ac-225-J591(a PSMA ligand) at Weill Cornell in NYC. It involves 8 visits over 12 weeks. Eligible patients must be metastatic and castration-resistant. They must have tried Zytiga, Xtandi and Taxotere or Jevtana. Scott Tagawa is the Principal Investigator.
Email: email@example.com. edu
(BTW - Scott Tagawa is also leading a trial combining two Lu-177-PSMA radiopharmaceuticals at Weill Cornell)